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DCs are professional antigen-presenting cells 
that are positioned throughout the peripheral 
immune system (1–3). DCs capture antigen 
and present processed antigenic peptides 
through MHC molecules (for review see 
references 4–7). Immature DCs migrate from 
the blood into tissues where they detect for-
eign antigens. Upon activation and maturation, 
these cells enlarge and migrate further to sec-
ondary organs where interaction with T cells 
can occur (8). HIV-1 infects permissive cells by 
interacting with CD4 molecules on the target 
cell and the gp120 subunit on the envelope of 
the virus (9, 10). This interaction causes a con-
formational change in the gp120 subunit, 
  allowing it now to interact with specifi  c 
G protein–coupled receptors of chemokines 
(11–15). Primary HIV-1 infections most com-
monly occur at mucosal surfaces of the human 
body, where immature DCs reside (16–22).
C-type lectins found on the surface of DCs 
have been implicated in binding viruses and 
  facilitating their uptake on mucosal surfaces 
(23–26). DC-SIGN, a major C-type lectin found 
on most but not all DCs, has been character-
ized as a gp120 binding protein of higher affi   n-
ity than CD4 (24). DC-SIGN facilitates rapid 
internalization of intact HIV-1 in both imma-
ture and mature DCs that contributes to en-
hanced infection in trans of target cells during 
formation of an infectious synapse (24, 27, 28). 
Both the dileucine and tyrosine-based motifs in 
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Dendritic cells (DCs) capture and internalize human immunodefi  ciency virus (HIV)-1 
through C-type lectins, including DC-SIGN. These cells mediate effi  cient infection of T cells 
by concentrating the delivery of virus through the infectious synapse, a process dependent 
on the cytoplasmic domain of DC-SIGN. Here, we identify a cellular protein that binds 
specifi  cally to the cytoplasmic region of DC-SIGN and directs internalized virus to the 
proteasome. This cellular protein, leukocyte-specifi  c protein 1 (LSP1), was defi  ned bio-
chemically by immunoprecipitation and matrix-assisted laser desorption/ionization time-of-
fl  ight mass spectrometry. LSP1 is an F-actin binding protein involved in leukocyte motility 
and found on the cytoplasmic surface of the plasma membrane. LSP1 interacted specifi  cally 
with DC-SIGN and other C-type lectins, but not the inactive mutant DC-SIGN∆35, which 
lacks a cytoplasmic domain and shows altered virus transport in DCs. LSP1 diverts HIV-1 to 
the proteasome. Down-regulation of LSP1 with specifi  c small interfering RNAs in human 
DCs enhanced HIV-1 transfer to T cells, and bone marrow DCs from lsp1−/− mice also 
showed an increase in transfer of HIV-1BaL to a human T cell line. Proteasome inhibitors 
increased retention of viral proteins in lsp1+/+ DCs, and substantial colocalization of virus 
to the proteasome was observed in wild-type compared with LSP1-defi  cient cells. Collec-
tively, these data suggest that LSP1 protein facilitates virus transport into the proteasome 
after its interaction with DC-SIGN through its interaction with cytoskeletal proteins.
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the cytoplasmic domain of the DC-SIGN molecule are criti-
cal for the internalization of HIV and other viruses (27, 29). 
Incoming HIV-1 particles in DCs are internalized by various 
DC-SIGN–dependent and –independent pathways. A frac-
tion of HIV-1 internalized in DCs is degraded immediately 
in the lysosomes. Some of the virus that escapes degradation 
is retained in endocytic compartments within the cytoplasm 
and is either transmitted by recycling to permissive CD4+ 
lymphocytes or degraded by the proteasome (30, 31). The 
process by which DC-SIGN internalizes and transfers HIV-1 
is thought to be mediated through classical endocytic and 
  recycling pathways (32); however, other cellular proteins 
  involved in this process are unknown. In this work, we describe 
an actin binding molecule, leukocyte-specifi  c protein 1 
(LSP1), which interacts with the cytoplasmic domain of 
DC-SIGN and aff  ects the transport of HIV-1 through the DC.
RESULTS
The cytoplasmic domain of DC-SIGN required for HIV-1 
internalization interacts with LSP1
DC-SIGN, a C-type lectin on immature DCs, mediates rapid 
internalization of intact HIV and contributes to enhanced in-
fection in trans of target cells that express CD4 and chemo-
kine receptors (24, 27). Raji B cells were fi  rst used to analyze 
the eff  ects of full-length DC-SIGN and DC-SIGN with 
  cytoplasmic domain truncations, DC-SIGN∆35, lacking both 
dileucine and tyrosine-based motifs, and DC-SIGN∆20, 
missing the dileucine motif. These DC-SIGN forms showed 
comparable cell surface expression, although the DC-SIGN∆35 
mutant showed slightly lower expression (Fig. 1 A). Also, 
human myeloid DCs (mDCs) cultured in GM-CSF or 
freshly isolated mDCs showed comparable surface expression 
of DC-SIGN compared with control stained cells (Fig. 1 B); 
however, less HIV-1 transfer to T cells occurs in those cells 
not cultured in GM-CSF (Fig. 1 C, right). Freshly isolated 
mDCs had previously been reported to express low levels of 
DC-SIGN that increase signifi  cantly after incubation with 
IL-4 (33). Compared with full-length DC-SIGN, when Raji 
B cells expressing DC-SIGN mutants were incubated with 
HIV-1ADA (CCR5 tropic) or HIV-1IIIB (CXCR4 tropic) at 
37°C for 2 h, washed, and incubated with A3R5 or MT2 
cells, they failed to mediate enhancement of T cell infection 
(Fig. 1 C). We and others have previously shown that Raji 
cells cannot be infected by HIV-1, and so all infection in Fig. 
1 C is mediated by trans-infection rather than cis-infection 
(22, 27). The DC-SIGN mutant data further support this 
conclusion, and direct capture of virus versus internalization 
in the Raji DC-SIGN and deletion mutants has been shown 
previously (27). In addition, CXCR4-tropic virus cannot 
infect mature or immature DCs (22). 20 μg/ml mAbs to 
DC-SIGN (BD Biosciences) completely inhibited HIV-1 
transfer by Raji B cells to MT2 T leukemia cells and partially 
inhibited transfer mediated by human DCs when incubated for 
2 h at 37°C before and during transfer of HIV-1ADA (Fig. 1 D). 
Collectively, these data suggest a role for DC-SIGN in 
  mediating uptake and transfer of the virus by human DCs.
To determine whether the cytoplasmic domain of DC-
SIGN was required for internalization, HIV-1–GFP-labeled 
virions were incubated with Raji B cell lines expressing WT 
DC-SIGN or DC-SIGN∆35. HIV-1–GFP-labeled virions 
were incubated at 4°C for 30 min to quantify cell surface 
binding. To assess internalization, cells were incubated with 
 780 ng/ml of HIV-1–GFP-labeled virions at 37°C for 2 h 
Figure 1.  DC-SIGN is necessary for HIV-1 uptake and transfer to 
T cells. (A) DC-SIGN expression on Raji B cells. Raji B cells expressing full-
length DC-SIGN, DC-SIGN∆35, and DC-SIGN∆20 were incubated with 
human mAb DC-SIGN/PE for 30 min at 4°C, washed once with PBS, and 
analyzed by fl  ow cytometry (MFI, mean fl  uorescence intensity). (B) DC-
SIGN expression on human mDCs. Immature human mDCs were incu-
bated with 2 μg of control or human mAb DC-SIGN (eBioscience) for 
30 min at 4°C, washed once with PBS, and incubated with donkey anti–
mouse Alexa 647–conjugated IgG for 30 min at 4°C, washed once with 
PBS, and analyzed by fl  ow cytometry. (C) Uptake and transfer of CCR5- 
and CXCR4-tropic HIV-1 by DC-SIGN. Raji B cells expressing full-length 
DC-SIGN, DC-SIGN∆35, and DC-SIGN∆20 were pulsed with 750 ng/ml 
HIV-1ADA (CCR5-tropic) or HIV-1IIIB (CXCR4) at 37°C for 2 h, trypsinized, 
washed, and incubated with A3R5 or MT2 cells, respectively. Also, human 
mDCs were pulsed with  780 ng/ml HIV-1ADA at 37°C for 2 h, trypsinized, 
washed, and incubated with A3R5. All cells were lysed 72 h after incuba-
tion and analyzed for luciferase activity. (D) mAbs to DC-SIGN inhibit 
uptake and transfer of HIV-1 into T leukemia cells by Raji B cells or hu-
man DCs. Raji B cells (left) expressing full-length DC-SIGN and human 
DCs (right) were incubated with mAb to DC-SIGN for 30 min at 4°C before 
incubating with 750 ng/ml HIV-1ADA for 2 h at 37°C. Cells were then 
washed and incubated with MT2 T leukemia cells. Cells were lysed 72 h 
after incubation and analyzed for luciferase activity.JEM VOL. 204, February 19, 2007  423
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and treated with trypsin for 5 min before being added to 
HeLa cells expressing CD4/CCR5 (MAGI-CCR5). Raji 
cells expressing DC-SIGN∆35 showed comparable cell sur-
face expression and were able to bind GFP-labeled HIV-1 
virions (Fig. 2 A). It has been shown previously (27) that 
HIV-1 pseudotypes bind to DC-SIGN and the other 
DC-SIGN mutants. However, in contrast to cells expressing 
WT DC-SIGN, cells with DC-SIGN∆35 did not inter-
nalize HIV-1 (Fig. 1, B and C, left vs. right panel). Thus, 
internalization appears to be critical for mediating trans-
  enhancement of HIV infection.
Because internalization and trans-enhancement of HIV 
infection are linked and mediated by the cytoplasmic region 
of DC-SIGN, we sought to identify cellular proteins that 
  interacted with this region. DC-SIGN, DC-SIGN∆35, and 
DC-SIGN∆20 were immunoprecipitated from whole cell 
extracts of their respective Raji lines with a DC-SIGN mAb 
that reacted with the extracellular portion of the molecule. 
The proteins in the immunoprecipitates were separated by 
two-dimensional gel electrophoresis and visualized by Coo-
massie blue staining. Two cellular proteins coprecipitated 
with WT DC-SIGN but were absent in DC-SIGN∆35 and 
DC-SIGN∆20 control samples. These proteins,  45 and 50 kD, 
were identifi  ed by matrix-assisted laser desorption/ionization 
time-of-fl  ight mass spectrometry as LSP1 (Fig. 3 A) and 
  actin (not depicted). To confi  rm the mass spectrometry data, 
Raji cells expressing DC-SIGN or the nonfunctional deletion 
mutants DC-SIGN∆35 and DC-SIGN∆20 were lysed and 
Figure 2.  The cytoplasmic domain of DC-SIGN is necessary for 
HIV-1 internalization. (A) Raji B cells expressing full-length DC-SIGN 
and cytoplasmic 35 amino acid–deleted DC-SIGN∆35 bind HIV-1. Ap-
proximately 780 ng/ml HIV-1 GFP-labeled (blue peak) and a No-Env nega-
tive control (red peak) virions were incubated with Raji cells expressing 
full-length and the cytoplasmic mutant DC-SIGN∆35 for 30 min at 4°C. 
Cells were then analyzed by fl  ow cytometry for cell surface–bound virus. 
(B and C) Raji cells expressing full-length DC-SIGN internalize HIV-1. Raji 
cells were incubated with HIV-1-GFP virions at 37°C for 2 h, trypsinized, 
washed, and added to HeLa cells expressing CD4/CCR5 (MAGI-CCR5) to 
visualize not only internalization, but polarization. Unlabeled arrows indi-
cate polarization of virus between cells. Cells were viewed using confocal 
microscopy (B, low magnifi  cation; C, high magnifi  cation) and analyzed 
using Leica software.
Figure 3.  LSP1 associates with the cytoplasmic domain of DC-
SIGN. (A) Identifi  cation of proteins interacting with the cytoplasmic do-
main of DC-SIGN. Raji cells, expressing DC-SIGN, DC-SIGN∆35, and 
DC-SIGN∆20 were lysed in cell lysis buffer and 2 mg of total protein was 
incubated overnight with 5 μg of monoclonal anti–DC-SIGN antibody 
and protein G conjugated to agarose beads at 4°C. The immunoprecipi-
tated material was washed and suspended in 2-D gel electrophoresis 
loading buffer. After 2-D gel electrophoresis, gels were stained with 
Coomassie blue. Coomassie-stained protein spots that were unique for 
the full-length DC-SIGN were picked, digested with trypsin, and analyzed 
by MALDI-TOF. A representation of the mass spectrometry data for the 
15–amino acid LSP1 peptide is shown (top). Protein sequence of LSP1 is 
shown, and the peptides identifi  ed by matrix-assisted laser desorption/
ionization time-of-fl  ight are underlined (bottom). (B) LSP1 interacts with 
full-length DC-SIGN but not the cytoplasmic tail–deleted mutant. The 
parental cell line Raji-1 and Raji B cells expressing DC-SIGN and nonfunc-
tional mutants DC-SIGN∆35 and DC-SIGN∆20 were lysed, and total pro-
tein was immunoprecipitated with monoclonal anti–DC-SIGN antibody 
and protein G conjugated to agarose beads overnight at 4°C. Immunopre-
cipitates were assayed for LSP1 (lanes 1–4) and DC-SIGN (lanes 5–8) ex-
pression using polyclonal antibodies by immunoblot. The control 
represents cell lysate from the parental cell line Raji-1. (C) LSP1 interacts 
with DC-SIGN in human DCs. Human MDDCs were isolated from healthy 
donors and cultured in RPMI, 50 ng/ml hGM-CSF, and 100 ng/ml IL-4 for 
7 d before being lysed, and total protein was immunoprecipitated in the 
presence of protease inhibitors with a monoclonal anti–DC-SIGN antibody 
conjugated to agarose beads. Immunoprecipitates were assayed for LSP1 
(lanes 9 and 10) and DC-SIGN (lanes 11 and 12) expression using polyclo-
nal antibodies by immunoblot.424  LSP1 TRAFFICS HIV-1 TO PROTEASOMES | Smith et al.
  total protein was immunoprecipitated with a monoclonal 
anti–DC-SIGN antibody conjugated to agarose beads. 
  Immunoblot of these precipitates showed that endogenous 
LSP1 interacted with the full-length DC-SIGN and partially 
with the DC-SIGN∆20 mutation; however, DC-SIGN∆35 
failed to interact with LSP1 (Fig. 3 B, lanes 1–4). The 
DC-SIGN immunoprecipitation experiments (Fig. 3 B) were 
performed with one mAb against the extracellular domain 
for immunoprecipitation, whereas a rabbit polyclonal anti-
body was used for Western blotting, and its reactivity with 
the mutant versus WT may diff  er and off  er a possible expla-
nation for the diff  erences in expression between DC-SIGN 
and DC-SIGN∆35. The interaction of DC-SIGN∆35 with 
LSP1 was also not seen when more lysate was used and nor-
malized to levels of DC-SIGN (not depicted). To determine 
if this interaction occurred in human DCs, monocyte-de-
rived DCs (MDDCs) were isolated from healthy donors and 
cultured in RPMI, 50 ng/ml hGM-CSF, and 100 ng/ml 
IL-4 for 7 d before being lysed, and total protein was immuno-
precipitated in the presence of protease inhibitors with a 
monoclonal anti–DC-SIGN antibody conjugated to agarose 
beads. Immunoblotting, as seen with the Raji cell line, 
  confi   rmed the interaction between DC-SIGN and LSP1 
(Fig. 3 C). MDDCs express higher levels of DC-SIGN when 
compared with human mDCs and can be isolated in greater 
cell numbers.
DC-SIGN binds to a distinct domain of LSP1 between 
amino acids 276 and 304
LSP1 is an F-actin binding protein involved in cell motility, 
cell adhesion, and IgM internalization (34–37). The caldesmon-
like (CI and CII) and villin-like (VI and VII) are two 
  domains on LSP1 that bind F-actin to facilitate neutrophil 
motility (38). To map the domain of LSP1 that interacted 
with DC-SIGN, stop codons (TAG) were introduced at 
amino acids 180, 275, and 305, generating several LSP1 mu-
tants (Fig. 4 A). LSP1(1–305) lacked the villin-like domains 
(VI and VII) and LSP1(1–275) contained only the caldesmon-
like (CI and CII) domains, whereas LSP1(1–180) lacked 
both the caldesmon-like (CI and CII) and villin-like (VI and 
VII) domains. LSP1 and the mutants were transfected with 
DC-SIGN in 293T cells. 72 h after transfection, cells 
were harvested, and cell lysates were immunoprecipitated 
with anti–DC-SIGN antibody. Immunoblots showed that 
DC-SIGN interacted with WT LSP1 and LSP1(1–305) 
that lacked villin-like domains but failed to interact with 
LSP1(1–275) that contained only the caldesmon-like 
domains and LSP1(1–180) that lacked both the caldesmon-
like and villin-like domains. These data show that amino 
  acids 276–304, which are independent of the F-actin binding 
regions, are essential for interaction between DC-SIGN and 
Figure 4.  DC-SIGN associates with LSP1 through a region distinct 
from its actin binding domains. (A) The caldesmon-like CI and CII 
(hatched) and villin-like VI and VII (gray) on LSP1 that bind F-actin are 
indicated. The early truncation mutants generated by site-directed muta-
genesis at amino acids 305, 275, and 180 are shown. (B) 293T cells 
(106 cells/well) in a six-well plate were cotransfected with full-length 
DC-SIGN and full-length LSP1 or the mutants (1–305, 275, and 180) as 
indicated. Cell lysates prepared 72 h after transfection were immuno-
precipitated with anti–DC-SIGN antibody and assayed for LSP1 (lanes 7–10) 
and DC-SIGN (lanes 11–14) by immunoblot. Cell lysates of transfected 
cells were analyzed by immunoblot for LSP1 expression in full-length and 
mutant 1–305, 1–275, and 1–180 constructs (lanes 15–18). (C) 35S-labeled 
in vitro–cotranslated full-length LSP1 interacts directly with DC-SIGN. Full-
length LSP1 or LSP1(1–180) cDNA were in vitro cotranslated with DC-
SIGN in rabbit reticulocytes in the presence of 35S. Labeled proteins were 
immunoprecipitated in the presence of protease inhibitors with mono-
clonal anti–DC-SIGN conjugated to agarose beads, electrophoresed on a 
10% polyacrylamide gel, and visualized by autoradiography. LSP1 and DC-
SIGN (lanes 1 and 3), DC-SIGN (lanes 2 and 4), and LSP1(1–180) (lane 4) 
are shown. (D) 293T cells (106 cells/well) in a six-well plate were cotrans-
fected with full-length LSP1 or LSP1(1–180) along with DC-SIGN, L-SIGN, 
and Langerin. Cell lysates prepared 72 h after transfection were immuno-
precipitated with anti–DC-SIGN, L-SIGN, or Langerin or mAbs, and immuno-
blotted with polyclonal antibody to LSP1 (lanes 1–6). Expression of 
full-length LSP1 and LSP1(1–180) in the cell lysate (lanes 7–12) is shown. 
DC-SIGN (lanes 13 and 14), L-SIGN (lanes 16 and 17), and Langerin (lanes 
19 and 20) expression in the cell lysates was assayed by immunoblot. The 
control is lysate from 293T cells transfected with a GFP plasmid. (E) LSP1 
interacts with other extracellular surface molecules. 293T cells (106 cells/
well) in a six-well plate were cotransfected with full-length LSP1 along 
with DC-SIGN, CD2, CD4, and CD40L. Cell lysates prepared 72 h after 
transfection were immunoprecipitated with anti–DC-SIGN, CD2, CD4, and 
CD40L mAbs and immunoblotted with polyclonal antibody to LSP1 (lanes 
1–4), or expression of full-length LSP1 in the cell lysate was determined 
(lanes 5–8). CD2 (lanes 9 and 10), CD4 (lanes 11 and 12), and CD40L (lanes 
13 and 14) expression in the cell lysates were assayed by immunoblotting. 
The control is lysate from 293T cells transfected with a GFP plasmid.JEM VOL. 204, February 19, 2007  425
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LSP1 (Fig. 4 B) and suggest that LSP1 interaction with the 
cellular cytoskeleton is required for its function. To deter-
mine if this interaction was direct or the product of multiple 
proteins, 35S-labeled in vitro cotranslated full-length LSP1 or 
LSP1(1–180) and DC-SIGN proteins were immunoprecipi-
tated in the presence of protease inhibitors with a mono-
clonal DC-SIGN antibody conjugated to agarose beads and 
electrophoresed on a 10% polyacrylamide gel. The proteins 
were visualized by autoradiography, showing a direct inter-
action between the full-length LSP1, but not the mutant 
(Fig. 4 C).
To examine the interactions of LSP1 with other C-type 
lectins, LSP1 and LSP1(1–180) were cotransfected with 
DC-SIGN, L-SIGN, and Langerin in 293T cells. Cell lysates 
were immunoprecipitated with the respective C-type lectin 
antibodies. Immunoblots revealed that all C-type lectins in-
teracted with LSP1 (Fig. 4 D, lanes 1–3) and not LSP1(1–180) 
(Fig. 4 D, lanes 4–6), suggesting a role for LSP1 in other 
C-type lectin-dependent processes. To address the binding 
specifi  city of C-type lectins’ cytoplasmic domain with LSP1, 
full-length LSP1 was also incubated with irrelevant molecules 
(CD2, CD4, and CD40L) and showed interaction with CD2 
and CD40L, but not the CD4 molecule (Fig. 4 E).
LSP1 down-modulation by specifi  c small interfering RNAs 
(siRNAs) in human DCs facilitates HIV-1 transfer to T cells
To determine whether LSP1 was detectable in immature and 
mature mDCs, mDCs from healthy individuals were exa-
mined before and after maturation with poly:IC. Both im-
mature and mature mDCs expressed LSP1, and the levels did 
not change with maturation (Fig. 5 A), even though HIV-1 
transfers more effi   ciently in mature mDCs (22). The physio-
logical consequences of LSP1–DC-SIGN interactions were 
further studied by LSP1-specifi  c siRNAs. Four LSP1-specifi  c 
siRNAs (Fig. 5 B) were synthesized, and their eff  ectiveness in 
down-regulating LSP1 was determined initially in Raji cells. 
Two siRNAs eff  ectively decreased endogenous LSP1 in Raji 
B cells (Fig. 5 B, siRNAs in A and C), and this knockdown 
was most effi   cient at 24 h, with LSP1 levels returning to nor-
mal in 48 h. Down-regulation of LSP1 did not change ex-
pression of DC-SIGN, CD80, or MHC class II; however, it 
enhanced the transfer of HIV-1 to T cells (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20061604/DC1).
To determine the eff   ect of HIV-1 internalization and 
transfer to T cells, human mDCs (incubated with poly:IC), 
MDDCs, and plasmacytoid DCs (pDCs) isolated from HIV-1− 
donors were transfected with the GeneSilencer reagent 
containing siRNAs for LSP1 (siC or siA) or a negative con-
trol (siRNA scramble). In transfected cells, siRNAs were 
mixed with an unrelated fl  uorescent Cy5-labeled scrambled 
siRNA at a ratio of 4:1 and identifi  ed by fl  ow cytometry 
after 8 h. Cells were sorted for the Cy5 label, plated onto a 
96-well tissue culture plate, and pulsed 24 h after transfection 
with a single round replication-competent virus expressing a 
luciferase reporter (HIV-1ADA) for 2 h at 37°C, washed, and 
incubated with A3R5 (CCR5-tropic) T leukemia cells. Cells 
were assayed for luciferase activity 72 h after transduction. 
The results demonstrate that LSP1 siRNA-treated Raji cells 
and various populations of human DCs facilitated greater 
Figure 5.  LSP1 down-regulation causes increased HIV-1 transfer 
in human DCs. (A) LSP1 expression in human DCs. Cell lysates prepared 
from immature or poly:IC-matured mDCs isolated from human elutriated 
monocytes were assayed for LSP1 expression by a polyclonal anti-LSP1 
antibody. Expression was measured against control cell lysates from 293T 
transfected with the LSP1 gene. (B) Specifi  c siRNAs for human LSP1 cause 
a down-regulation of LSP1 expression. Raji–DC-SIGN cells were trans-
fected with the indicated LSP1, and control siRNA duplexes were intro-
duced by nucleofection. 24 h after transfection, cell lysates (20 μg of 
total protein) were assayed for LSP1 expression by immunoblot (left). The 
fi  lm images were digitized using an Epson scanner and quantifi  ed using 
Bio-Rad Quantity One software. The numbers obtained for LSP1 were 
corrected using the numbers obtained from actin and plotted relative to 
control in a Microsoft Excel graph as indicated (right). (C and D) Down-
regulation of human LSP1 in human DCs and Raji DC-SIGN cell line 
causes an increase in HIV-1 transfer to T cells. Mature human DCs were 
transiently transfected by GeneSilencer with siRNA for LSP1 (siA and siC) 
or scrambled siRNA (control). To label transfected cells, unrelated Cy5 
siRNA was mixed with both control siRNA and LSP1 siRNAs at a ratio of 
4:1. 8 h after the siRNA transfection, the cells were sorted for the Cy5 
label and plated onto 96-well plates. 24 h after transfection, cells were 
pulsed with luciferase expressing 780 ng/ml HIV-1ADA for 2 h at 37°C, 
washed fi  ve times, and incubated with A3R5 T cells. Cells were lysed 72 h 
after transfection and analyzed for luciferase activity. These experiments 
were performed in three independent HIV-1− donors in triplicate samples, 
and two such experiments are represented in the fi  gure.426  LSP1 TRAFFICS HIV-1 TO PROTEASOMES | Smith et al.
transfer of HIV-1 to T cells compared with control (Fig. 5, 
C and D). These data suggest that LSP1 interacts with 
DC-SIGN and/or other C-type lectins to direct the virus 
away from pathways mediating trans-infection.
Increased HIV-1 transfer to human T cells by lsp1−/− DCs
To investigate the role of LSP1 in HIV-1 traffi   cking through 
DCs, we fi  rst determined whether DCs from LSP1 knockout 
mice conferred the same enhancement of infection to T cells 
observed in human DCs. To test this hypothesis, bone 
marrow–derived DCs (BMDCs) were isolated from lsp1+/+ 
and lsp1−/− mice (34). DCs were incubated with CpG oligo-
nucleotide for 24–48 h to induce maturation. Total protein 
from immature and mature BMDCs was assayed for LSP1 
expression. As with human DCs, expression levels were not 
aff  ected by maturation (Fig. 6 A), and lsp1−/− DCs were null 
for LSP1 (Fig. 6 B). To determine the eff  ect of LSP1 in mu-
rine DCs, mature BMDCs from lsp1+/+ and lsp1−/− mice 
were incubated with live HIV-1BaL ( 780 ng/ml) for 2 h at 
37°C, washed extensively, and incubated alone or with A3R5 
T cells. p24 levels were assayed in supernatants 72 h after in-
fection. Similar to knockdown in human DCs, murine DCs 
that lacked LSP1 increased transfer of virus to T cells (Fig. 6 C). 
Because the murine DCs mimic the eff  ect seen in human 
DCs, they were used to further understand the mechanisms 
of LSP1-mediated HIV-1 internalization and the infection 
of T cells.
DC LSP1 traffi  cs HIV-1 to the proteasome for degradation
Incoming HIV-1 particles in DCs are bound and internalized 
by various DC-SIGN–dependent and –independent path-
ways. Immediately after internalization, most of the virions 
are degraded in an acidic lysosomal compartment. A fraction 
of the virus that escapes degradation is retained in endocytic 
compartments and is either transmitted to permissive CD4+ 
lymphocytes or degraded by the proteasome (30, 31). To in-
vestigate the role of LSP1 in DC processing and transport of 
HIV-1, HIV-1–GFP was incubated with DCs in the pres-
ence or absence of proteasome or lysosome inhibitors. 
  Because of the inability to confi  rm the complete silencing of 
LSP1 and the limited window of knockdown in human 
mDCs, the LSP1 knockout mice provide the best model sys-
tem to study the degradative pathway in the total absence 
of LSP1. Diff  erentiated BMDCs were incubated with the 
  lysosomal inhibitors chloroquine (100 μM), the endosome 
acidifi  cation inhibitor bafi  lomycin A1 (10 μg/ml), or the 
proteasomal inhibitor MG132 in RPMI (5 μg/ml) or RPMI 
alone for 1 h before transduction with concentrated HIV-1–
GFP for 2 h. Cells were washed extensively and incubated 
with the respective inhibitors. Before lysis, cells were treated 
with trypsin and washed to remove virus bound to the cell 
surface. Total protein isolated at various time points after the 
2-h transduction (0 h, 1 h, and 3 h) was assayed by ELISA for 
p24 Gag. Results at 1 h showed that more retention of HIV-1 
occurred in lsp1−/− BMDCs when compared with lsp1+/+ 
controls (Fig. 7 A, left). The p24 values at other times showed 
a similar trend as the 1-h time point, but the eff  ect was 
maximal at 1 h. In lsp1+/+ control cells treated with the pro-
teasome inhibitor MG132, HIV-1 retention was higher com-
pared with chloroquine-, bafi  lomycin-,  or  vehicle-treated 
lsp1+/+ cells (Fig. 7, middle) and were similar to lsp1−/− BMDCs 
when treated with the same inhibitors (Fig. 7, right), suggest-
ing that LSP1 may be involved in the shuttling of virus to the 
proteasome for degradation.
To determine the colocalization of HIV-1 to the protea-
some in DCs, mature BMDCs from lsp1−/− and wt mice 
were pulsed with HIV-1–GFP for 30 min at 37°C. For pro-
teasome inhibitor studies, BMDCs from lsp1−/− and wt mice 
were incubated with the proteasomal inhibitor MG132 in 
RPMI (5 μg/ml) or RPMI alone for 1 h before infection by 
concentrated HIV-1–GFP for 30 min. Cells were washed ex-
tensively and stained with a mAb to the 20S proteasome sub-
unit a-4. BMDCs from lsp1−/− mice showed more HIV-1 
retention and less colocalization to the proteasome (Fig. 7 B). 
In contrast, those cells from wt mice showed greater colocali-
zation of HIV-1 to the proteasome (Fig. 7 B, yellow). Once 
DCs were treated with the proteasome inhibitor MG132, 
colocalization was markedly diminished in both lsp1−/− and 
Figure 6.  Murine DCs from lsp1−/− mice increase HIV-1 uptake 
and transfer to T cells. (A) LSP1 expression in murine DCs remains con-
stant after maturation. Cell lysates prepared from immature or CpG-
matured bone marrow–derived murine DCs were assayed for LSP1 expression 
by a polyclonal anti-LSP1 antibody. (B) LSP1 expression in mature BMDCs 
isolated from lsp1−/−, lsp1+/−, and lsp1+/+ littermates. Cell lysates pre-
pared from CpG-matured bone marrow–derived murine DCs were assayed 
for LSP1 expression by a polyclonal anti-LSP1 antibody. (C) LSP1-null 
BMDCs enhance HIV-1 trans-infection of T cells. Mature BMDCs (105/well) 
from WT (wt) or lsp1−/− mice were pulsed with HIV-1BaL ( 780 ng/ml of 
p24/ml) or RPMI alone for 2 h at 37°C. Cells were washed extensively to 
remove free virus and replaced with fresh media, and A3R5 T cells were 
added to one set of mock or HIV-1–infected BMDCs followed by incuba-
tion for another 72 h. At the appropriate time, cell supernatants were 
collected, and p24 ELISA was performed as instructed by the manufac-
turer (Coulter). The data are representative of duplicate experiments.JEM VOL. 204, February 19, 2007  427
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wt mice (Fig. 7 C). Collectively, these results are consistent 
with the model that LSP1 shuttles the internalized pool of 
HIV-1 to the proteasome and that lack of LSP1 facilitates 
HIV-1 transfer.
DISCUSSION
In this study, we have demonstrated that DC-SIGN, a 
C-type lectin on DCs that mediates HIV-1 uptake and transfer 
to T cells, interacts with LSP1, an actin-binding cytoskeletal 
protein. HIV-1 uptake is dependent on the cytoplasmic do-
main of the DC-SIGN molecule (Fig. 1). By using immuno-
precipitation for biochemical purifi  cation and identifi  cation 
by mass spectrometry, we showed that LSP1 interacts specifi  -
cally with this cytoplasmic region. Our results also show that 
LSP1 interacts with other C-type lectins, L-SIGN and Lan-
gerin, which are present on the human DC. Because these 
C-type lectins have been shown to mediate HIV-1 transfer 
independently of DC-SIGN (39), LSP1 may be involved 
with these C-type lectins’ interaction with HIV-1. Langerin, 
unlike DC-SIGN, contains a proline-rich region that is likely 
responsible for binding and rapid internalization of patho-
gens. CD2 and CD40L both contain this proline-rich region, 
possibly providing the region necessary for interaction with 
LSP1. Down-regulation of LSP1 siRNAs in human DCs or 
murine lsp1−/− BMDCs showed a dramatic increase in the 
amount of virus transferred from the DC to the susceptible 
T cell, as LSP1 was shown to facilitate proteasomal degradation 
of HIV-1.
A leukocytic protein, LSP1 (also known as WP34, pp52, 
and leufactin) is a 52-kD F-actin binding phosphoprotein 
expressed in all human leukocytes and leukocytic cell lines 
(40–42). The basic C-terminal domain contains amino acid 
sequences homologous to two known F-actin binding pro-
teins, caldesmon and the villin headpiece (36, 37). Although 
LSP1 is an F-actin binding protein, it is also a very important 
regulator of microfi  lamentous cytoskeleton dynamics (34). 
After HIV-1 uptake in the DCs, it is internalized into a spe-
cialized viral endosome, which is distinct of early and late 
  endosomal vesicles (43), where a fraction of virus remains 
undigested and polarizes to the infectious synapse between 
the targeted T cells (24, 27, 28). HIV-1 virus that does not 
polarize is subjected to lysosomal processing and MHC II 
antigen presentation, or it is degraded by the proteasome 
(30, 31). Because LSP1 interacts specifi  cally with full-length 
DC-SIGN and not a truncated cytoplasmic domain mutant, 
this fi  nding suggests that it is involved with traffi   cking HIV 
through the DC. LSP1 has proven important in polarizing 
the actin cytoskeleton and aiding in motility of the cell. Us-
ing proteasome inhibitors and confocal microscopy, we show 
that LSP1 helps to shuttle the HIV-1 virus into the protea-
some, promoting its degradation, a process independent of its 
interaction with DC-SIGN. In the absence of LSP1, HIV-1 
degradation decreases and more virus is able to recycle to the 
surface, promoting transfer to T cells. We do not know why 
the proteasomes in murine DCs were not susceptible to 
  bafi  lomycin as they are in human DCs. Because they are 
Figure 7.  LSP1 traffi  cs HIV-1 to the proteasome. (A) HIV-1 degra-
dation is decreased in lsp1−/− DCs, and proteasome inhibitors block HIV-1 
degradation in the presence of LSP1. Mature BMDCs from lsp1−/− and wt 
mice were pulsed with HIV-1–GFP for 2 h at 37°C, washed with PBS, 
trypsinized, and lysed with p24 lysis buffer reagent (left). Mature BMDCs 
from wt (lsp1+/+) were pretreated for 1 h with MG132 (proteasome in-
hibitor), chloroquine, or bafi  lomycin A-1 (lysosomal inhibitors) in RPMI or 
RPMI alone in a 96-well tissue culture dish (5 × 104 cells). Cells were then 
pulsed with HIV-1–GFP for 2 h at 37°C in the presence of inhibitors, 
washed with PBS, replaced with media containing the respective inhibi-
tors, and incubated for an additional 1 h. Cells were then trypsinized, 
washed, and lysed with p24 lysis buffer reagent (right). p24 Gag concen-
trations were assayed by ELISA. These data are representative of the 1-h 
time point from multiple experiments performed in triplicate. The per-
centage values were calculated by setting the amount of p24 measured 
immediately after removing the virus from the cells, the 0-h time point, to 
100%. The differences in p24 after several hours were then measured and 
compared with the 0-h time point. (B and C) HIV-1 shows greater colo-
calization with the proteasome in DCs expressing LSP1. (B) Mature BMDCs 
from lsp1−/− (−/−) and wt (+/+) mice were pulsed with HIV-1–GFP 
(green) for 30 min at 37°C. For proteasome inhibitor studies, BMDCs from 
lsp1−/− and wt mice were incubated with the proteasomal inhibitor 
MG132 in 5 μg/ml RPMI or RPMI alone for 1 h before infection by HIV-1–
GFP (green) for 30 min. Cells were washed, fi  xed, and stained with a mAb 
to the 20S proteasome subunit a-4 (red) and viewed using confocal 
microscopy. HIV-1 that colocalizes with proteasomes appears yellow 
(overlay). (C) HIV-1 colocalization with proteasomes is representative of a 
percentage of HIV-1 that colocalizes with a percentage of proteasomes 
above a measurable threshold. Percentage colocalization was calculated 
using the Leica confocal software. Three images/sample were used, and 
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  isolated diff  erently from the human cells and are grown in 
cytokines, it is possibly a diff  erence in the patterns of gene 
expression in these cells, although we cannot exclude a spe-
cies eff  ect. Proteasomal inhibitors can aff  ect ubiquitin levels 
in the cells, which could explain the decrease in HIV-1 deg-
radation; however, in the absence of LSP1, there was less co-
localization of HIV-1 to the proteasome and no signifi  cant 
diff   erence in HIV-1 degradation in the lsp1−/− BMDCs 
compared with wt cells treated with proteasomal inhibitors, 
suggesting that this eff  ect was independent of ubiquitin 
  eff  ects. This experiment confi  rmed the role of LSP1 in this 
degradative process.
Our study reveals new insights into HIV-1 traffi   cking 
through DCs leading to the enhancement of T cell infection 
by DC-SIGN–internalized virus. The role of DC-SIGN in 
trans-infection is not completely understood, in part because 
other C-type lectins may be involved in the process in some 
DC populations, and blocking of DC-SIGN with mAbs does 
not always completely inhibit HIV-1 transfer. Although one 
previous study contradicted the report of Kwon et al. (27) 
that point mutants in the tyrosine and dileucine motifs of the 
cytoplasmic domain of DC-SIGN do not aff  ect gp120 bind-
ing, it is important to recognize that the latter study analyzed 
internalization with gp120 protein rather than virus (44), and 
the signifi   cance of this assay for virus internalization and 
transfer is questionable. Nonetheless, consistent with the pre-
sent work, a mutant with a deletion of the cytoplasmic do-
main in that study showed the same loss of function as seen 
here examined by transmission of the lentiviral vector.
The discovery that LSP1, an actin-binding molecule, in-
teracts with DC-SIGN has implications for understanding 
the trans-enhancement of T cell infection by DCs, possibly 
leading to ways of blocking transfer. Sequestering actin and 
the cytoskeleton may lead to decreased transfer of HIV-1, but 
not without possible serious eff  ects on DC viability. Antigen 
internalized by DCs has been shown to lead to classical MHC 
II processing, peptide loading, and surface presentation (45). 
We fi  nd that increased transfer of HIV-1 to T cells in the ab-
sence of LSP1 is due to decreased HIV-1 degradation in the 
proteasome; however, insights into the eff  ect of LSP1 on 
peptide processing and antigen presentation have yet to be 
investigated. Collectively, these data suggest a role for LSP1 
traffi   cking of HIV-1 to the proteasome for viral degradation. 
Continued elucidation of HIV-1 traffi   cking in DCs provides 
us with a greater understanding of how C-type lectins, such 
as DC-SIGN, mediate viral uptake and transfer to susceptible 
target cells.
MATERIALS AND METHODS
Plasmids and siRNA. The DC-SIGN CITE-GFP and DC SIGN∆35 
CITE-GFP were expressed under a CMV promoter/enhancer. The 
cDNA-encoding LSP1 (accession no. BI911034) was expressed in pCMV-
SPORT6 (Invitrogen). Mutagenesis of LSP1 was performed using a Strata-
gene Quick Change Site-Directed Mutagenesis kit according to the 
manufacturer’s directions. To introduce a stop codon to generate LSP1 
(1–305, 275, and 180) mutants, the following primers were used: LSP1(1–305): 
5′ primer: G  G  G  A  G  G  C  T  C  C  A  A  G  A  C  C  T  C  A  T  A  A  T  C  T  A  G  A  T  C  A  A  C  A  A  T-
T  A  A  G  A  G  C  A  C  C  C  C  ; LSP1(1–275): 5′ primer: G  G  T  G  A  G  G  T  A  C  A  G  G  C  T-
C  A  G  T  C  T  T  A  A  T  C  T  A  G  A  G  C  G  G  C  C  A  A  G  A  C  T  C  C  G  T  C  C  ; and LSP1(1–180): 
5′ primer: C C  C  A  G  C  C  C  C  T  T  G  G  T  C  T  T  G  T  A  A  T  C  T  A  G  A  G  A  G  G  G  G  A  C  C-
A  T  C  G  A  A  C  A  G  A  G  C  . Only the sense strands of the mutagenesis primers are 
shown. The PCR products were digested with DpnI at 37°C for 1 h per 
the manufacturer’s protocol and transformed into TOP10 (Invitrogen) cells. 
A pool of siRNAs specifi  c for human LSP1 was designed based on the cDNA 
gene sequence. LSP1 siRNA duplexes siRNA LSP1-a (5′-C  A  G  G  A  G  G  A  G  C-
A  C  C  A  G  A  A  A  U  -3′), siRNA LSP1-b (5′-G  U  C  C  A  C  C  U  G  G  A  G  G  A  G  U  U-
G  A  -3′), LSP1-c (5′-U  G  G  A  G  A  C  A  U  G  A  G  C  A  A  G  A  A  A  U  U  -3′), LSP1-d 
(5′-C  C  U  G  A  G  C  C  C  U  A  C  C  A  C  C  A  A  A  U  U  -3′), and negative control 
(5′-U  U  C  U  C  C  G  A  A  C  G  U  G  U  C  A  C  G  U  dTdT-3′) siRNAs were manufac-
tured by QIAGEN. Cy5 siRNA was made by Dharmacon Inc.
Virus production, entry, transduction, and infection assays. Pseudo-
typed HIV-1ADA lentivirus-expressing luciferase was prepared by transient 
cotransfection of 293T cells using calcium phosphate (Promega). In brief, 
the packaging vector pMD 8.2, pHR-luciferase, and the envelope express-
ing vector pSVIII-HIVADA or pRSV-HIVIIIB were transiently transfected 
into 293T cells. Supernatants were harvested 48 and 72 h after transfection, 
fi  ltered, and stored at −80°C. Virus concentration was determined by an 
ELISA assay for the p24 antigen (Beckman Coulter) (16–22).
GFP-Vpr–labeled HIV-1 lentivirus (HIV-1–GFP) was produced by 
transfection of 293 T cells with the pLAI provirus and the plasmid pEGFP- 
C3 (CLONTECH Laboratories, Inc.) containing the entire Vpr coding re-
gion fused to the carboxyterminus of eGFP (GFP-Vpr). Cells were washed 
at 16–20 h after transfection and replenished with fresh media. 48 h later, su-
pernatants were harvested, fi  ltered through a 0.45-μm syringe fi  lter, and 
concentrated. In brief, 32 ml of supernatant was layered on 5 ml of Optiprep 
(Iodoxinal) medium (Invitrogen) and centrifuged at 50,000 g for 1.5 h with 
a Surespin 630 rotor (Sorvall). The last 3 ml of supernatant remaining above 
the Optiprep interface was collected and frozen at −80°C in 500-μl aliquots 
(27, 29). Concentrated HIV-1BaL (MOI,  1; 7.8 μg/ml p24) was prepared 
in PBMCs and provided by J. Mascola and M. Louder (Vaccine Research 
Center, NIAID, NIH).
24 h after transfection of siRNAs, HIV-1ADA infection was performed in a 
96-well fl  at-bottomed luciferase culture plate by removing 200 μl RPMI cul-
ture media and adding 200 μl of virus stock. After incubation for 2 h at 37°C, 
cells were washed twice and incubated with 1.5 × 105 A3R5 T cells for 48 h, 
lysed, and assayed for luciferase activity with a commercially available kit (Pro-
mega). Similarly, BMDCs from LSP1 transgenic mice were infected with WT 
HIV-1BaL (MOI,  1; μg/ml 7.8 p24) for 2 h and washed fi  ve times with RPMI. 
All animal experiments were reviewed and approved by the Animal Care and 
Use Committee, Vaccine Research Center (VRC), NIAID, and performed in 
accordance with all relevant federal and NIH guidelines and regulations. The 
DCs were incubated with A3R5 T cells for 48 h and assayed for p24.
Lsp1+/− and C57BL/6 wt mouse BMDCs were isolated and incubated 
in 20 ng/ml RPMI plus GM-CSF in a 96-well tissue culture dish (5 × 104). 
The cells were matured in 5 μg/ml of ODN CpG (1829) for 24–48 h. Cells 
were pretreated with 10 μg/ml bafi  lomycin, 5 μg/ml MG132, 100 μM 
chloroquine, or alone in RPMI for 1 h. Media were then removed, and DCs 
were pulsed with HIV-1–GFP for 2 h. Cells were washed once with PBS 
and lysed in 1X p24 cell lysis buff  er at time points 0 h, 1 h, and 3 h and stored 
at −30°C. Lysates were assayed for p24 activity by ELISA (Beckman Coulter 
HIV-1 p24 Antigen EIA) and read at 450/570 nm dual wavelength on a 
SPECTRAmax Plus 384 (16–22).
Cells and transfections. Parental control Raji-1 cells and Raji-1 cells sta-
bly transfected with human DC-SIGN (Raji DC-SIGN) or DC-SIGN with 
a cytoplasmic truncation that lacks both the dileucine motif and the tyrosine-
based motif in the cytoplasmic tail (Raji DC-SIGN∆35 and DC-SIGN∆20) 
were provided by D. Littman (New York University School of Medicine, 
New York, NY) and maintained in RPMI media at 37°C and 5% CO2. 
A3R5 T cells were provided by J. Mascola (Vaccine Research Center, 
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Human mDCs and pDCs were purifi  ed from elutriated monocytes from 
healthy adult donors by a two-step procedure consisting of automated leu-
kapheresis and counterfl  ow centrifugal elutriation at the Transfusion Medi-
cine Department of the Warren Grant Magnuson Clinical Center, NIH. 
Because the cells only are used and are without identifi  ers, this work with 
the cells is exempt from IRB review. mDCs and pDCs were isolated from 
the elutriated monocyte fraction with negative selection by removing cells 
expressing BDCA-4 and CD19 with microbeads (Miltenyi Biotec), followed 
by positive selection using antibodies to CD1c (Miltenyi Biotec). mDCs 
and pDCs were then cultured in a medium containing 10 ng/ml GM-CSF 
(PeproTech) for 18–24 h before any experiments. mDCs were also induced 
to mature using 50 μg/ml poly:IC (Sigma-Aldrich) for 48 h. Human MDDCs 
were generated from monocytic cells cultured in RPMI, hGM-CSF, and 
IL-4 for 7 d before phenotyping cells for CD11c to ensure purity.
Lsp1−/−, lsp1+/−, and C57BL/6 mice (The Jackson Laboratory) were 
killed by cervical dislocation to ensure that the animal would not revive. 
  Femurs were then removed, excising the muscle and fat from the bone. 
Once the bone was exposed, the upper and lower knobs of the bone were 
removed, exposing the shaft. The shaft was then fl  ushed with PBS plus 
2X penicillin streptomycin by a 27-gauge needle and syringe. Cells were 
harvested, centrifuged, and resuspended in 1 ml RPMI plus GM-CSF 
(20 ng/ml). The cells were then cultured for 7 d, adding 30 ml of RMPI 
plus GM-CSF (20 ng/ml) every 3 d. The total cell volume was then har-
vested and resuspended in RPMI plus GM-CSF. BMDCs were matured us-
ing 5 μg/ml ODN CpG (1829) for 24–48 h. All animal experiments were 
approved by IACUC and conducted in compliance with all relevant federal 
and NIH policies.
Matured human DCs were transfected with a control of LSP1 siRNA 
(QIAGEN). For each transfection, 225 nM siRNA (180 nM unlabeled 
siRNA and 45 nMCy5-labeled siRNA) was used. Transfections were 
performed in a 4:1 mixture of unlabeled siRNA and Cy5. To tranfect the 
mature human DCs with siRNA, 106 cells were resuspended in 1 ml of 
serum-free RPMI. The siRNA mixture was combined with 9 μl of Gene-
Silencer (Genlantis) and added to the cell suspension according to the manu-
facturer’s protocol. The cells were washed 8 h after transfection and sorted 
by a fl  uorescence-activated cell sorter (Becton Dickinson) to identify Cy5-
labeled siRNA-transfected cells. Sorted cells were seeded in a 96-well plate 
at 5 × 104 cells/well.
Immunoprecipitation, immunoblot, and mass spectrometry. Raji 
cells expressing DC-SIGN or a nonfunctional mutant, DC-SIGNΔ35 or 
DC-SIGNΔ20, were lysed in 1X cell lysis buff  er (Cell Signaling). 1 or 2 mg 
of total protein was incubated with monoclonal anti–DC-SIGN antibody 
for 2 h. Protein G (Invitrogen) conjugated to agarose beads was then added 
and incubated overnight at 4°C. The mixture was washed three times with 
1X cell lysis buff  er and loaded onto a polyacrylamide 4–12% gel for 1-D or 
2-D electrophoresis. Gels were stained with Coomassie blue or proteins 
were transferred to a PVDF membrane (Invitrogen) and assayed for LSP1 
and DC-SIGN by immunoblot using polyclonal antibodies.
Protein identifi  cation of 1-D or 2-D gel-separated proteins was per-
formed on reduced and alkylated, trypsin-digested samples prepared by 
standard mass spectrometry protocols. Tryptic digests were chromato-
graphed (1 μl/min), and peptides were separated using a Zorbax C18SBW 
reverse phase column (0.15 mm ID × 100 mm). The mobile phase con-
sisted of a gradient prepared from solvent A (0.2% formic acid) and solvent 
B (99.8% acetonitrile, 0.2% formic acid) at room temperature. For these 
fractionated digests, capillary LC-tandem MS (LC-MS/MS) was performed 
with a CapLC and a quadruple-time of fl  ight mass spectrometer (Qtof-2; 
Waters Micromass). Computer-controlled data-dependent automated 
switching to MS/MS provided peptide sequence information. MassLynx 
and Global Server software were used for data acquisition and processing. 
Data processing and databank searching were performed with Mascot soft-
ware (Matrix Science). The NCBInr protein database from The National 
Center for Biotechnology Information, NLM/NIH, was used for the 
search analysis.
35S-labeled in vitro transcription translation. Full-length LSP1 or 
LSP1(1–180) cDNAs were in vitro cotranslated with DC-SIGN in rabbit 
reticulocytes in the presence of 35S (TNT-sport6; Promega). Labeled pro-
teins were immunoprecipitated in the presence of protease inhibitors with 
monoclonal anti–DC-SIGN conjugated to agarose beads electrophoresed on 
a 10% polyacrylamide gel. The gel was fi  xed and dried using a slab gel dryer 
(Savant SGD 2000) at 80°C for 5 h. Labeled proteins were visualized by 
  autoradiography after 9 h.
Confocal microscopy. 105 Raji B cells expressing full-length DC-SIGN 
and cytoplasmic 35 amino acid–deleted DC-SIGN∆35 were incubated with 
100 μl of a GFP-labeled HIV-1 pseudolentivirus for 2 h. Cells were treated 
with trypsin-EDTA, washed, and added to MAGI-CCR5 HeLa cells 
(104 cells/well) plated onto eight-well coverslip slides (Nunc). Sequential 
images of live cells were recorded every 3 min by confocal microscopy 
(SP2-AOBS; Leica Microsystems), and uptake, polarization, and transfer 
were assessed with representative cells.
105 mature BMDCs from lsp1−/− and wt mice were pulsed with 100 μl 
HIV-1–GFP for 30 min at 37°C. For proteasome inhibitor studies, BMDCs 
from lsp1−/− and wt mice were incubated with the proteasomal inhibitor 
MG132 in 5 μg/ml RPMI or RPMI alone for 1 h before infection by con-
centrated HIV-1–GFP for 30 min. Cells were washed once with PBS plus 
2% FCS, fi  xed, permeablized (BD Biosciences), and stained with a mAb 
(15 μg/ml) to the 20S proteasome subunit a-4 (BioMol). Cells were viewed 
using confocal microscopy and analyzed using Leica software.
Online supplemental material. Fig. S1 demonstrates that LSP1 down-
regulation causes increased HIV-1 transfer in Raji B cells that does not aff  ect 
normal surface receptor expression. Fig. S1 is available at http://www.jem
.org/cgi/content/full/jem.20061604/DC1.
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